Добірка наукової літератури з теми "666.266.6 : 666.293"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "666.266.6 : 666.293".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "666.266.6 : 666.293"
1
Lar, Claudia, Gheorghe-Doru Roiban, Romina Crăsneanu, Ilişca Mihalca, Elena Bogdan, Anamaria Terec, and Ion Grosu. "Synthesis and photophysical properties of some 6,6″-functionalized terpyridine derivatives." Open Chemistry 9, no. 2 (April 1, 2011): 218–23. http://dx.doi.org/10.2478/s11532-010-0146-4.
Повний текст джерелаАнотація:
AbstractThe synthesis and photophysical properties of several 6,6″ symmetrically substituted 4′-aryl-2,2′:6′,2″-terpyridine derivatives are reported herein. The UV-Vis spectra in acetonitrile as well as in dichloromethane show two intense bands in the UV areas 252–262 nm and 275–290 nm while the fluorescence emission spectra are only slightly influenced by chemical derivatization.
2
Leonard, B. E. "Neuropeptide Y protocols. Edited by A. Balasubramaniam. Humana Press, Totowa, New Jersey, 2000. Pages: 246. ISBN: 0-89603-662-6." Human Psychopharmacology: Clinical and Experimental 16, no. 6 (2001): 487–88. http://dx.doi.org/10.1002/hup.293.
Повний текст джерела
3
Cammell, S. B., D. E. Beever, J. D. Sutton, J. France, the late G. Alderman, and D. J. Humphries. "An examination of energy utilization in lactating dairy cows receiving a total mixed ration based on maize silage." Animal Science 71, no. 3 (December 2000): 585–96. http://dx.doi.org/10.1017/s1357729800055314.
Повний текст джерелаАнотація:
AbstractSix multiparous Holstein-Friesian cows were offered a total mixed ration based on maize silage in a repeated measure design to evaluate the partition of gross energy (GE) during early to mid lactation. Four measurements were made at 6-week intervals with energy and nitrogen balances carried out in open-circuit respiration chambers over 6 days during lactation weeks 6, 12, 18 and 24. The intakes of total diet dry matter (DM) corrected for volatile losses (VCDM), organic matter (OM) and GE declined significantly (P< 0•01) as lactation progressed, although apparent digestibility of these fractions was not altered, resulting in a significant (P< 0•01) decline in digestible nutrient intake at each stage of lactation. Methane and urine energy losses were not significantly affected, resulting in significantly (P< 0·001) higher amounts of digestible energy (DE) partitioned to methane and urine as lactation progressed with associated significant reductions in metabolizable energy (ME) intake (MEI) (P< 0·01) and ME as a proportion of DE (P< 0·001) and GE (q) (P< 0·05). With advancing lactation there was a significant (P< 0·001) increase in the amount of ME partitioned to heat (HP/MEI), but no significant change in the amount partitioned to milk and tissue. Individual values for diet metabolizability (ME/GE) at actual (production) levels (qa) (mean 0·625 MJ/MJ) were corrected to an equivalent value at maintenance (qmc) (mean 0·666 MJ/MJ). The overall ME intakes (MJ/day) were: ad libitum, 246, corrected for level of feeding effect, 263, with a predicted ME requirement according to AFRC (1993) (MER93) of 242. Substitution of the calculated qmc into the predictive equations (AFRC, 1993) resulted in a mean maintenance requirement of 57·6 MJ/day (0·464 MJ/kg M0·75/day) whilst the mean value derived from the linear model describing the experimental data was 82·5 MJ/day (0·664 MJ/kg M0·75/day). The mean efficiencies of utilization of ME for milk production derived from AFRC (1993) and the linear regression model were 0·653 MJ/MJ and 0·625 MJ/MJ respectively.
4
Sorigue, Marc, Juan-Manuel Sancho, Santiago Mercadal, Ruben Fernández-Álvarez, Helena Pomares, Olga Garcia, Eva González-Barca, et al. "Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy." Blood 126, no. 23 (December 3, 2015): 1510. http://dx.doi.org/10.1182/blood.v126.23.1510.1510.
Повний текст джерелаАнотація:
Abstract Background: Follicular lymphoma (FL) is the most frequent indolent lymphoma and is characterized by a high response to immunochemotherapy (ICT). However, patients refractory to first-line ICT have a worse prognosis. The objective of this study was to determine the prevalence of refractory FL, the factors that predict refractoriness as well as the salvage treatment and outcome. Patients and methods: This is a retrospective analysis including stage II-IV FL patients treated with first-line ICT in 3 Spanish institutions. The cohort was divided into ICT-refractory patients (less than partial response after induction or maintenance/consolidation therapy, as well as relapse or progression within 6 months of the last dose of therapy) and ICT-sensitive. Baseline features, therapy received and outcome were analyzed. Results: 283 patients were included, the median age was 58 years-old (range 28 to 85) and 53% were female. 200/231 (87%) had a good performance status (ECOG < 2), 260/295 (88%) presented with stages III and IV and 163/284 (57%) had bone marrow involvement. High-risk FLIPI score was seen in 108/256 (42%), high serum LDH in 78/263 (28%) and high serum B2-microglobulin in 138/253 (54%). RCHOP was administered to 226 (80%), RCVP to 36 (13%) and rituximab in combination with fludarabine or bendamustine-based therapy to 21 (7%). Seventeen patients received consolidation with radioimmunotherapy and 140 received maintenance with rituximab (n=137) or interferon (n=3). Sixteen patients received complementary radiotherapy. Forty-three (16%) patients were ICT-refractory (37 within 6 months of the completion of induction and 6 during or within 6 months of the completion of maintenance/consolidation therapy). On univariate analysis, high-risk FLIPI (OR 5.4, [95% CI 2.3-12.6]), high-risk FLIPI2 (5.4, [2.4-12.4]), B symptoms (3.2, [1.6-6.6]), ECOG ≥ 2 (4.6, [2-10.9]), involvement of > 4 nodal regions (2.3, [1.02-5.3]), hepatomegaly (7.5, [2.6-21.5]), splenomegaly (2.8, [1.4-5.9]), high B2-microglobulin (4, [1.7-9.5]), high serum LDH (3.9, [1.8-8]) and treatment with RCVP (compared with RCHOP, 2.8, [1.2-6.2]) were correlated with refractoriness. On multivariate analysis, high-risk FLIPI score (4.9, [2.1-11.7]) and treatment with RCVP (3.4, [1.2-9.4]) were the only variables associated with refractoriness. After exclusion of FLIPI, ECOG ≥ 2 (3, [1.1-8.4]) and high serum LDH (4.7, [2-11]) were correlated with refractoriness, in addition to RCVP therapy (4.5, [1.5-13.2]). Ten-year OS probabilities in ICT-sensitive and ICT-refractory patients were 83% (95% CI 76%-90%) and 33% (12%-54%), respectively (p<0.001) (Figure 1). ICT-refractory patients were more likely to be also refractory to second-line therapies than ICT-sensitive patients (21/31 [68%] vs 10/58 [17%], p<0.001). In addition, histological transformation was suspected by clinical or biological features or confirmed by tissue biopsy in 11/43 ICT-refractory and 8/240 ICT-sensitive (p<0.0001). Death among ICT-refractory patients was more frequently due to lymphoma than in ICT-sensitive patients (19/23 [83%] vs 14/28 [50%], p=0.033). Conclusions: In this series of FL treated with first-line ICT, the prevalence of refractoriness was low and occurred most frequently during or within 6 months of induction rather than maintenance/consolidation therapy. FLIPI score and RCVP treatment (compared to RCHOP) were predictive of refractoriness. The response rate of ICT-refractory FL patients to second-line therapy is low and the prognosis is poor. Supported in part by RD12/0036/0029 del RTICC, Instituto Carlos III. Figure 1. Overall survival in immunochemotherapy (ICT)-sensitive and ICT-refractory patients (p<001) Figure 1. Overall survival in immunochemotherapy (ICT)-sensitive and ICT-refractory patients (p<001) Disclosures Sancho: CELLTRION, Inc.: Research Funding. Sureda:Seattle Genetics Inc.: Research Funding; Takeda: Consultancy, Honoraria, Speakers Bureau.
5
Golubev, A. M., A. V. Grechko, V. E. Zakharchenko, M. M. Kanarsky, M. V. Petrova, and I. V. Borisov. "Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke." General Reanimatology 17, no. 5 (October 23, 2021): 23–34. http://dx.doi.org/10.15360/1813-9779-2021-5-23-34.
Повний текст джерелаАнотація:
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In recent years considerable attention has been given to the study of molecular markers of ischemic and hemorrhagic strokes. These studies are relevant because brain-specific protein biomarkers of neurons and glial cells can provide valuable and timely diagnostic information necessary for clinical decision-making.The aim of the study was to reveal the differences in the serum level of molecular markers in acute, subacute and early recovery periods of ischemic and hemorrhagic strokes.Material and methods. The study included 59 patients. Twenty patients were diagnosed with hemorrhagic stroke and 39 had ischemic stroke. The control group included 20 volunteers. Serum levels of molecular CNS markers were determined in acute, subacute, and early recovery stages of stroke. The serum levels of CNS molecular markers of patients with ischemic and hemorrhagic stroke was measured quantitatively by enzyme immunoassay. Statistical analysis was performed by nonparametric Mann-Whitney method.Results. The level of brain-derived neurotrophic factor (BDNF) in the control volunteers was 574.5 [455.5; 615] pg/ml. Significant differences were found for acute and subacute periods of hemorrhagic stroke: it was 674 [560; 749] pg/ml (P=0.003) and 664 [616; 762] pg/ml (P=0.0001).The level of neuron-specific enolase was significantly increased in all periods of the study: it was 4.15 [3.53; 4.8] ng/ml in the control group, 5.4 [4.4; 6.4] ng/ml in acute period of ischemic stroke (P<0.001), 5.4 [4.4; 6.4] ng/ml in early recovery period of ischemic stroke (P=0.001), 5.1 [4.6; 6.4] ng/ml in acute period of hemorrhagic stroke (P=0.014), 664 [616; 762] ng/ml in subacute period of hemorrhagic stroke (P=0.003).In the control group, the serum S-100 protein level was 4.5 [3.8; 5.4] ng/ml. In the acute and early recovery periods of ischemic stroke, S-100 protein level has significantly fallen down to 4.1 [3.4; 4.6] ng/ml (P<0.031) and 3.9 [3.4; 6] ng/ml (P=0.014), respectively. Glial-cell derived neurotrophic factor level was 1.98 [1.64; 2.1] ng/ml in the controls and increased up to 2.4 [2.2; 5] ng/ml (P=0.002) in the acute period and 2.4 [2.3; 2.6] ng/ml (P<0.001) in the subacute period of hemorrhagic stroke.The vascular endothelial growth factor receptor-1 (VEGFR-1) was significantly lower in the subacute period of hemorrhagic stroke: 485 [211; 945] pg/ml in the subacute period vs 903.5 [626; 1115] pg/ml in the controls (P=0.001).Conclusion. We found differences in the serum level of molecular markers in patients with ischemic and hemorrhagic strokes. In the acute period, early recovery period of ischemic stroke, and subacute period of hemorrhagic stroke, there was an increase in the serum level of neuron-specific enolase. The level of brain-derived neurotrophic factor increased significantly in the acute and subacute periods of hemorrhagic stroke. In the acute and early recovery periods of ischemic stroke, the level of S-100 protein decreased. The level of glial cell-derived neurotrophic factor increased in the acute and subacute periods of hemorrhagic stroke. In the subacute period of hemorrhagic stroke, the level of endothelial growth factor receptor-1 significantly decreased. Moreover, there was significant difference between values of this parameter in the subacute period of hemorrhagic stroke and in the early recovery period of ischemic stroke.
6
Edgell, G. J. "Book reviewsBrick and block masonry Editor: de CourcyJ. W. Elsevier Applied Science, Barking, 1988. 234 mm × 152 mm. 3 volumes: 594 pp., 658 pp., 666 pp. Illustrated, hardback. 1 85166 262 6; 1 85166 263 4; 1 85166 264 2 £160 (3 volumes)." Magazine of Concrete Research 41, no. 147 (June 1989): 115. http://dx.doi.org/10.1680/macr.1989.41.147.115.
Повний текст джерела
7
Seita, Y., S. Sugio, D. Sano, M. Nakada, M. Hoshina, Y. Okuda, J. Ito, and N. Kashiwazaki. "273 REMOVAL OF ACROSOME FROM SPERM HEADS IMPROVES DEVELOPMENT OF RAT ZYGOTES THROUGH INTRACYTOPLASMIC SPERM INJECTION." Reproduction, Fertility and Development 20, no. 1 (2008): 216. http://dx.doi.org/10.1071/rdv20n1ab273.
Повний текст джерелаАнотація:
In intracytoplasmic sperm injection (ICSI), sperm chromatin is introduced into the oocyte together with acrosome, which does not enter cytoplasm of oocytes during normal fertilization. In mice, acrosome of sperm head has a detrimental effect on embryonic development of the ICSI oocytes (Morozumi et al. 2006 Proc. Natl. Acad. Sci. USA 103, 17 661–17 666). We examined the effect of acrosome removal of frozen/thawed (F/T) rat sperm on development to term of the ICSI oocytes in order to improve production efficiency of live offspring from F/T rat spermatozoa through ICSI. In experiment 1, epididymal spermatozoa of the Wistar rats were frozen as described previously (Seita et al. 2005 Reprod. Fertil. Dev. 18, 256 abst). The F/T spermatozoa were sonicated to separate sperm heads. The sperm heads were divided into 3 treatment groups; nontreated sperm head (control), sperm heads exposed in 0.02% of Triton X-100 solution for 1 min (TX), sperm heads exposed in 0.02% lysolectin solution for 1 min (LL). Acrosomal status of the sperm heads was then examined by FITC-peanut agglutinin stain. In experiment 2, sperm heads of the control, TX, and LL treatments were microinjected into denuded oocytes obtained from superovulated females (Hirabayashi et al. 2002 Transgenic Res. 11, 221–228). The ICSI oocytes were cultured and observed for the formation of pronuclei (2PN) for 6 h and blastocyst formation at 120 h of culture. In experiment 3, the ICSI oocytes cultured for 6 h were transferred to recipient females to examine development to term. Statistical analyses of the results were carried out by 1-way ANOVA. In experiment 1, the TX (76%) and LL (89%) treatments showed higher rates of acrosome removal than that of the control (24%) group (P < 0.05). In experiment 2, the percentage of 2PN formation at 6 h after ICSI was not significantly different among sperm-treated groups, although the TX (76%) and LL (70%) groups were higher than the control (24%) group at 4 h (P < 0.05). The percentages of blastocyst formation were not significantly different among sperm-treated groups (control: 10%; TX: 25%; and LL: 25%). In experiment 3, the efficiency of development to term of the TX treatment group (21%: 12/57) was significantly higher than the control (5%: 3/55; P < 0.05), although the LL treatment group (16%: 12/75) was not significantly different from the control and TX treatment groups. These results indicate that acrosome removal using TX of F/T rat sperm heads before ICSI improves development to term of the ICSI oocytes. This benefical effect of acrosome removal may be due to the quick release of sperm-activating factors from sperm heads after ICSI in the rat.
8
Roll, Stephanie, Marc Nocon, and Stefan N. Willich. "Reduction of common cold symptoms by encapsulated juice powder concentrate of fruits and vegetables: a randomised, double-blind, placebo-controlled trial." British Journal of Nutrition 105, no. 1 (August 23, 2010): 118–22. http://dx.doi.org/10.1017/s000711451000317x.
Повний текст джерелаАнотація:
Dietary supplements have been suggested in the prevention of the common cold, but previous investigations have been inconsistent. The present study was designed to determine the preventive effect of a dietary supplement from fruits and vegetables on common cold symptoms. In a randomised, double-blind, placebo-controlled trial, healthcare professionals (mainly nursing staff aged 18–65 years) from a university hospital in Berlin, Germany, were randomised to four capsules of dietary supplement (Juice Plus+®) or matching placebo daily for 8 months, including a 2-month run-in period. The number of days with moderate or severe common cold symptoms within 6 months (primary outcome) was assessed by diary self-reports. We determined means and 95 % CI, and differences between the two groups were analysed by ANOVA. A total of 529 subjects were included into the primary analysis (Juice Plus+®: 263, placebo: 266). The mean age of the participants was 39·9 (sd 10·3) years, and 80 % of the participants were female. The mean number of days with moderate or severe common cold symptoms was 7·6 (95 % CI 6·5, 8·8) in the Juice Plus+® group and 9·5 (8·4, 10·6) in the placebo group (P = 0·023). The mean number of total days with any common cold symptoms was similar in the Juice Plus+® and in the placebo groups (29·4 (25·8, 33·0) v. 30·7 (27·1, 34·3), P = 0·616). Intake of a dietary supplement from fruits and vegetables was associated with a 20 % reduction of moderate or severe common cold symptom days in healthcare professionals particularly exposed to patient contact.
9
Shiga, Kazuyoshi, Masayasu Hara, Takaya Nagasaki, Takafumi Sato, Hiroki Takahashi, Mikinori Sato, and Hiromitsu Takeyama. "Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients." Gastroenterology Research and Practice 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/9701574.
Повний текст джерелаАнотація:
Aims. To evaluate the prognostic significance of serum interleukin-6 (IL-6) in colorectal cancer (CRC).Patients and Methods. Preoperative serum IL-6 was measured in 233 CRC patients and 13 healthy controls. Relationships between IL-6 and various clinicopathological factors were evaluated, and the overall survival (OS) and disease-free survival (DFS) rates according to IL-6 status were calculated for all patients and according to disease stage.Results. The mean IL-6 level was 6.6 pg/mL in CRC patients and 2.6 pg/mL in healthy controls. Using a cutoff of 6.3 pg/mL, obtained using receiver operating characteristic curve analysis, 57 patients had a high IL-6 level. The mean value was higher for stage II disease than for stage III disease. IL-6 status correlated with C-reactive protein (CRP) and carcinoembryonic antigen levels, obstruction, and pT4 disease. The OS differed according to the IL-6 status for all patients, whereas the DFS differed for all patients and for those with stage II disease. The Cox proportional hazards model showed that pT4 disease was an independent risk factor for recurrence in all CRC patients; IL-6, CRP, and pT4 were significant risk factors in stage II patients.Conclusions. The preoperative IL-6 level influences the risk of CRC recurrence.
10
Jassem, Jacek, Roy S. Herbst, Filippo de Marinis, Jacques Cadranel, Tibor Csőszi, Dolores Isla, Gongyan Chen, et al. "IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e21623-e21623. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e21623.
Повний текст джерелаАнотація:
e21623 Background: IMpower110 evaluated atezo mono in PD-L1–selected, chemo-naive patients (pts) with nonsquamous (nsq) or squamous (sq) NSCLC. At the interim analysis, IMpower110 met its primary OS endpoint, with a statistically significant and clinically meaningful improvement for atezo vs chemo in TC3 or IC3 wild-type ( EGFR/ALK-negative) pts. We report on the safety profile of atezo vs chemo in IMpower110. Methods: 572 pts with stage IV nsq or sq NSCLC, PD-L1 expression ≥ 1% on TC or IC and ECOG PS 0-1 were randomized 1:1 to receive atezo (1200 mg IV q3w) or chemo (4 or 6 21-day cycles). In the chemo arm, nsq pts received cisplatin (cis) 75 mg/m2 or carboplatin (carbo) AUC 6 + pemetrexed (pem) 500 mg/m2 IV q3w; sq pts received cis 75 mg/m2 + gemcitabine (gem) 1250 mg/m2 or carbo AUC 5 + gem 1000 mg/m2 IV q3w. Safety was assessed in all treated pts (safety evaluable [SE] population [pop]), regardless of PD-L1 expression or EGFR/ALK status. AEs were summarized per MedDRA v22.0 and severity graded per NCI CTCAE v4.0. Immune-mediated AEs (imAEs) were defined per a sponsor-specified list of terms, regardless of whether the events led to systemic glucocorticoid, endocrine therapy, or other immunosuppressants use. Results: At data cutoff (Sep 10, 2018) within the ITT pop, treatment (tx) was ongoing in 90 (atezo: 31.6%) and 25 (chemo: 8.7%) pts, with 13.7 mo of follow-up. Within the SE pop (atezo: n = 286, chemo: n = 263), atezo pts had longer tx exposure (5.3 mo) vs chemo pts (pem, 3.5 mo; gem, 2.6 mo; carbo, 2.3 mo; cis, 2.1 mo). Atezo had a favorable safety profile vs chemo (table); safety data were consistent with data from a pooled atezo mono pop. imAEs occurred in 40.2% (atezo) and 16.7% (chemo) of pts and were Grade (Gr) 3-4 in 6.6% and 1.5%, respectively. Conclusions: Atezo was better tolerated than chemo and imAEs were generally low grade. Overall, the safety experience with atezo mono in IMpower110 was consistent with its known safety profile; no new safety signals were identified. Clinical trial information: NCT02409342. [Table: see text]
Частини книг з теми "666.266.6 : 666.293"
1
Taber, Douglass F. "C–H Functionalization: The Maimone Synthesis of Podophyllotoxin." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0021.
Повний текст джерелаАнотація:
Matthias Beller of the Universität Rostock developed (Angew. Chem. Int. Ed. 2014, 53, 6477) a Rh catalyst for the acceptorless dehydrogenation of an alkane 1 to the alkene 2. Bhisma K. Patel of the Indian Institute of Technology Guwahati effected (Org. Lett. 2014, 16, 3086) oxidation of cyclohexane 3 and 4 to form the allylic benzoate 5. Justin Du Bois of Stanford University devised (Chem. Sci. 2014, 5, 656) an organocatalyst that mediated the hydroxylation of 6 to 7. Vladimir Gevorgyan of the University of Illinois, Chicago hydrosilylated (Nature Chem. 2014, 6, 122) 8 to give an intermediate that, after Ir-catalyzed intramolecular C–H functionalization followed by oxidation, was converted to the diacetate 9. Sukbok Chang of KAIST used (J. Am. Chem. Soc. 2014, 136, 4141) the methoxime of 10 to direct selective amination of the adjacent methyl group, leading to 11. John F. Hartwig of the University of California, Berkeley effected (J. Am. Chem. Soc. 2014, 136, 2555) diastereoselective Cu-catalyzed amination of 12 with 13 to make 14. David W. C. MacMillan of Princeton University accomplished (J. Am. Chem. Soc. 2014, 136, 6858) β-alkylation of the aldehyde 15 with acrylonitrile 16 to give 17. Yunyang Wei of the Nanjing University of Science and Technology alkenylated (Chem. Sci. 2014, 5, 2379) cyclohexane 3 with the styrene 18, leading to 19. Bin Wu of the Kunming Institute of Botany described (Org. Lett. 2014, 16, 480) the Pd-mediated cyclization of 20 to 21. Similar results using Cu catalysis were reported (Angew. Chem. Int. Ed. 2014, 53, 3496, 3706) by Yoichiro Kuninobu and Motomu Kanai of the University of Tokyo and by Haibo Ge of IUPUI. Jin-Quan Yu of Scripps La Jolla constructed (J. Am. Chem. Soc. 2014, 136, 5267) the lactam 24 by γ-alkenylation of the amide 22 with 23, followed by cyclization. Philippe Dauban of CNRS Gif-sur-Yvette prepared (Eur. J. Org. Chem. 2014, 66) the useful crystalline chiron 27 by asymmetric amination of the enol triflate 26 with 25. Matthew J. Gaunt of the University of Cambridge showed (J. Am. Chem. Soc. 2014, 136, 8851) that the phenylative cyclization of 28 with 29 to 30 proceeded with near-perfect retention of absolute configuration.
2
Taber, Douglass. "Heterocycle Construction: The Chang Synthesis of Louisianin C." In Organic Synthesis. Oxford University Press, 2011. http://dx.doi.org/10.1093/oso/9780199764549.003.0069.
Повний текст джерелаАнотація:
It has been known for some time that an acid chloride 1 can be added to an alkyne 2 to give the β-chloro enone. Yasushi Tsuji of Kyoto University found (J. Am. Chem. Soc. 2009, 131, 6668) that with an Ir catalyst, the condensation of 1 with 2 could be directed to the furan 3. Huanfeng Jiang of the South China University of Technology described (Organic Lett. 2009, 11, 1931) a complementary route to furans, Cu-mediated condensation of a propargyl alcohol 4 with the diester 5 to give 6. Bruce A. Arndtsen of McGill University developed (Organic Lett. 2009, 11, 1369) an approach to pyrroles such as 9, by condensation of an α,β-unsaturated α-cyano imine 7 with the acid chloride 8. Thomas J. J. Müller of Heinrich-Heine-Universität Düsseldorf observed (Organic Lett. 2009, 11, 2269) the condensation of an acid chloride 11 with a propargyl amine 10, leading to the iodo pyrrole 12. John A. Murphy of the University of Strathclyde uncovered (Tetrahedron Lett. 2009, 50, 3290) a new entry to the Fischer indole synthesis, by Petasis homologation of a hydrazide 13. Dali Yin of Peking Union Medical College took advantage (Organic Lett. 2009, 11, 637) of the easy sequential displacement of the fluorides of 15, leading, after acid-catalyzed cyclization, to the indole 17. Kang Zhao of Tianjin University extended (Organic Lett. 2009, 11, 2417; Organic Lett. 2009, 11, 2643) his studies of oxidation of an enamine 18 to the 2H -azirine, that on heating cyclized to the indole 19. Peter Wipf of the University of Pittsburgh established (Chem. Commun. 2009, 104) a microwave-promoted indole synthesis, illustrated by the intramolecular Diels-Alder cyclization of 20 to 21. A review delineating all nine types of indole syntheses will appear shortly in Angewandte Chemie . Fushun Liang and Qun Liu of Northeast Normal University demonstrated (J. Org. Chem. 2009, 74, 899) that the readily-prepared ketene thioacetal 22 condensed with NH3 to give the pyridine 23. Sundaresan Prabhakar and Ana M. Lobo of the New University of Lisbon observed (Tetrahedron Lett. 2009, 50, 3446) that the addition of the alkoxy propargyl amine to the alkyne 25 gave a Z alkene, that on warming rearranged to the pyridine 26.
3
Taber, Douglass F. "Organic Functional Group Transformation." In Organic Synthesis. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780199965724.003.0007.
Повний текст джерелаАнотація:
Susumu Saito of Nagoya University developed (Angew. Chem. Int. Ed. 2011, 50, 3006) Fe-catalyzed conditions, compatible with alkenes, for converting an alcohol 1 to the amine 2. Corey R. J. Stephenson of Boston University took advantage (Nature Chem. 2011, 3, 140) of photoredox catalysis to convert an alcohol 3 to the iodide 4. Jing-Mei Huang of the South China University of Technology condensed (J. Org. Chem. 2011, 76, 3511) the halide 5 with benzaldehyde and aqueous ammonia to give the imine 6. Young Hoon Jung of Sungkyunkwan University used (Tetrahedron Lett. 2011, 52, 1901) chlorosulfonyl isocyanate to convert a benzylic (or allylic) ether 7 into the urethane 8. David Crich of Centre de Recherche de Gif coupled (Org. Lett. 2011, 13, 2256) the isocyanate 9 with the acid 10 to give the amide 11. Tobias Ritter of Harvard University effected (J. Am. Chem. Soc. 2011, 133, 1760) α-hydroxylation of the acidic ketone 12 by exposure to O2 in the presence of a Pd catalyst. Gowravaram Sabitha of the Indian Institute of Chemical Technology, Hyderabad, activated (Org. Lett. 2011, 13, 382) Pd(OH)2 by exposure to H2 , then used the activated catalyst to isomerize the allylic alcohol 14 to the aldehyde 15 . Richard C. Hartley of the University of Glasgow combined (Tetrahedron Lett. 2011, 52, 3020) commercial Nysted reagent and Cp2 TiCl2 to methyl-enate the ester 16. The enol ether 17 is a versatile intermediate, giving, inter alia, the methyl ketone by hydrolysis, or the α-hydroxy ketone on exposure to peracid. The activation of alkynes continues to be an area of vigorous investigation. Lukas Hintermann of the Technische Universitä t München devised (J. Am. Chem. Soc. 2011, 133, 8138) a Ru catalyst for the hydration of 18 to the aldehyde 19. Issa Yavari of Tarbiat Modares University effected (Tetrahedron Lett. 2011, 52, 668) oxidation of 20 to the N-sulfonyl amidine 22. Craig A. Merlic of UCLA coupled (Org. Lett. 2011, 13, 2778) 24 with the vinyl boronate derived from 23 to give the silyl enol ether 25. Li-Biao Han of AIST Tsukuba prepared (Chem. Commun. 2011, 47, 2333) 28 by adding 27 to 26.
4
Taber, Douglass F. "Carbon-Carbon Bond Formation." In Organic Synthesis. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780199965724.003.0025.
Повний текст джерелаАнотація:
Akiya Ogawa of Osaka Prefecture University found (Tetrahedron Lett. 2010, 51, 6580) that the Sm-mediated reductive coupling of a halide 1 with CO2 to give the carboxylic acid 2 was strongly promoted by visible light. Gregory C. Fu of MIT designed (Angew. Chem. Int. Ed. 2010, 49, 6676) a Ni catalyst for the coupling of a primary borane 4 with a secondary alkyl halide 3. James P. Morken of Boston College devised (Org. Lett. 2010, 12, 3760) conditions for the carbonylative conjugate addition of a dialkyl zinc to an enone 6 to give the 1,4-dicarbonyl product 7. Louis Fensterbank of the Institut Parisien de Chimie Moléculaire developed (Angew. Chem. Int. Ed. 2010, 49, 8721; not illustrated) a protocol for the conjugate addition of alkyl boranes to enones. Hyunik Shin of LG Life Science, Daejeon, and Sang-gi Lee of Ewha Womans University showed (Tetrahedron Lett. 2010, 51, 6893) that the intermediate from Blaise homologation of a nitrile 8 was a powerful nucleophile, smoothly opening an epoxide 10 to deliver 11. Sébastien Reymond and Janine Cossy of ESPCI ParisTech found (J. Org. Chem. 2010, 75, 5151) that FeCl3 smoothly catalyzed the coupling of an alkenyl Grignard 13 with the primary iodide 12. The Ti-mediated coupling of an alkyne 16 with an allylic alkoxide 15 (J. Am. Chem. Soc. 2010, 132, 9576) developed by Glenn C. Micalizio of Scripps/Florida was the key step in the total synthesis (J. Am. Chem. Soc. 2010, 132, 11422) of lehualide B. Huanfeng Jiang of the South China University of Technology observed (Chem. Commun. 2010, 46, 8049) that KI added to a bromoalkyne 18 to give the dihalide 19 with high geometric control. Haruhiko Fuwa of Tohoku University improved (Org. Lett. 2010, 12, 5354) the selective hydroiodination of a methyl alkyne 20 to 21. Takuya Kurahashi and Seijiro Matsubara of Kyoto University devised (Chem. Commun. 2010, 46, 8055) the Ni-catalyzed three-component coupling of an alkyne 22, methyl acrylate 23, and phenyl isocyanate to give the doubly homologated lactam 24. Patrick H. Toy of the University of Hong Kong showed (Synlett 2010, 1997; Org. Lett. 2010, 12, 4996 for a polymer with covalently attached base) that resin-bound triphenylphosphine participated efficiently in the Wittig coupling of 26 with an aldehyde 25.
Тези доповідей конференцій з теми "666.266.6 : 666.293"
1
Shevnin, I. A., O. N. Ragozin, O. V. Ragozina, N. A. Ilyushchenko, and B. Z. Jafarova. "he specifics of posture formation among schoolchildren living in the city of Khanty-Mansiysk against the background of undifferentiated connective tissue dysplasia." In VIII Vserossijskaja konferencija s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka». Publishing center of Ulyanovsk State University, 2021. http://dx.doi.org/10.34014/mpphe.2021-236-239.
Повний текст джерелаАнотація:
Undifferentiated forms of DST are widespread among children living in Khanty-Mansiysk, in connection with which it is relevant to assess the influence of this pathology on the formation of posture in schoolchildren of the North. Determination of the type of posture and the identification of stigmas of dysembryogenesis was carried out in 208 schoolchildren of the city of Khanty-Mansiysk. Posture types were divided into: normal, round, flat and stooped. Participants with the number of stigmas from 0 to 5 were allocated to the comparison group (n = 66), the rest (6 or more) made up the study group (n = 143). A card was entered, including 43 hair dryers. The study found that the incidence of UCTD among children in the Khanty-Mansi Autonomous Okrug-Yugra is noticeably higher than among those living in temperate latitudes and has a negative effect on the formation of posture.
Key words: North, posture, physical development, undifferentiated connective tissue dysplasia.
2
Poll, C. T., P. A. Kyrle, and J. Westwick. "ACTIVATION OF PROTEIN KINASE C INHIBITS THROMBIN AND FLUORIDE STIMULATED EICOSANOID PRODUCTION IN HUMAN PLATELETS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644633.
Повний текст джерелаАнотація:
Touqui et al (1986) have suggested that phosphorylation by protein kinase C of a 1ipomodulin-1 ike polypeptide extracted from platelets renders it inactive as an inhibitor of phospholipase A2. We have examined this suggestion by measuring thromboxane (Tx) B2 generation and cytosolic free calcium concentration ([Ca++]i) in stimulated, washed human platelets loaded with or without quin-2. Addition of thrombin (0.077, 0.23, 0.77, 2.3 and 7.7 nM) to control platelets produces a dose-related elevation of [Ca++]i (10±5, 50±7, 260±30, 550±25 and 1500±100 nM respectively) and generation of TxB2 (0, 9±4, 45±6, 194±10 and 375±30 pmoles/108 platelets respectively). Preincubation of platelets for 1 min with 1-oleoyl-2-acetyl-rac-glycerol (OAG, 22-198 μM), phorbol myristate acetate (PMA, 1.616 nM) or EGTA (2 mM) produces a marked inhibition of high and low dose thrombin (7.7 nM and 0.77 nM) or NaF (18 mM) induced elevation of [Ca++]i and TxB2 generation. Pretreatment of platelets with the protein kinase C inhibitor, H-7 (60 uM), prevented the inhibition of TxB2 formation induced by PMA (4.816 nM) or OAG (66-198 μM) in either thrombin (0.77 nM) or NaF (18 mM) stimulated platelets. When arachidonic acid (AA, 10 μM) is used as the stimulus, the Δ[Ca++]i is 190±15 nM and TxB2 generation is 35.9±2 pmoles/108 platelets. While pretreatment with 4.8 nM PMA obliterates the AA-induced Δ[Ca++]i and partially reduces (p< 0.05) the TxB2 generation to 27.8+3 pmoles/108 platelets. PMA and OAG pretreatment also inhibits TxB2 generation in thrombin-stimulated, non-quin-2-1oaded platelets. Thus, at least with intact, agonist- and NaF-stimulated platelets, activation of protein kinase C inhibits eicosanoid production.We thank the British Heart Foundation and Ciba-Geigy USA for financial support.
3
Moraes, Yasmin Oliveira, Milean Joel Costa De Brito, Ney Pereira Carneiro Dos Santos, Marianne Rodrigues Fernandes, and Darlen Cardoso De Carvalho. "PREVALÊNCIA DE MUCOSITE ORAL EM PACIENTES PORTADORES DE CÂNCER GASTROINTESTINAL SUBMETIDOS À QUIMIOTERAPIA COM 5-FLUOROURACIL, EM DOIS HOSPITAIS DE REFERÊNCIA EM ONCOLOGIA NA REGIÃO NORTE DO BRASIL." In III Congresso Brasileiro de Ciências Farmacêuticas On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/conbracif/33.
Повний текст джерелаАнотація:
Introdução: A mucosite oral (MO) consiste em uma reação inflamatória aguda na mucosa bucal sendo uma das complicações mais comuns do tratamento com o quimioterápico 5-Fluorouracil (5-FU), podendo levar a várias complicações incluindo dor intensa, diarreia e desnutrição. Essas complicações, além de comprometer a qualidade de vida do paciente oncológico, podem levar a interrupções no tratamento quimioterápico, o que pode reduzir sua sobrevida. Objetivos: Determinar a prevalência de MO em pacientes com diagnóstico de câncer gástrico e colorretal, tratados com o quimioterápico 5-FU, isolado ou em combinação, entre os anos de 2017 e 2018, em dois hospitais de referência no tratamento oncológico localizados na cidade de Belém- PA (Unidade de Alta Complexidade em Oncologia-UNACON e Ophir Loyola-HOL). Material e Métodos: O estudo tem caráter transversal, descritivo e quantitativo e foi aprovado pelo comitê de ética em pesquisa (protocolo 231.244/2013). Dados epidemiológicos e clínicos foram coletados dos prontuários médicos de 216 pacientes e posteriormente foram analisados no programa estatístico SPSS v.25. Resultados: Entre os pacientes incluídos no estudo, 92 (42,6%) tinha o diagnóstico de câncer gástrico e 124 (57,4%) de câncer colorretal, 112 (51,8%) pacientes eram do gênero masculino e 104 (48,2%) do feminino. A média de idade dos participantes foi de 54 anos. Todos os pacientes receberam 5-FU, isoladamente (7,4%) ou em associação com outros fármacos, sendo o esquema de tratamento mais frequente 5-FU combinado a leucovorin (41,2%), seguido por FOLFOX (5-FU, leucovorin, oxaliplatina) 40,3% e FOLFIRI (5-FU, irinotecano e leucovorin) 11,1%. A maioria dos pacientes analisados possuíam estadiamento tumoral avançado grau III (42, 6%) e IV (39, 8%). Durante o tratamento, 50 pacientes (23, 1%) apresentaram MO, a maior parte desses pacientes apresentavam câncer colorretal (66%) e eram gênero feminino (24%). A média de idade entre os pacientes com MO foi de 54,3 anos e a maioria recebeu o esquema terapêutico FOLFOX (40%). Conclusão: Foi observado no estudo uma alta prevalência de MO em pacientes portadores de câncer gastrointestinal tratado com 5-FU. Esses dados servem de alerta para elaboração de abordagens preventivas e terapêutica para a MO, a fim de melhorar a qualidade de vida dos pacientes oncológicos.